Genoway SA
PAR:ALGEN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.36
4.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genoway SA
Net Margin
Genoway SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | FR |
| Market Cap | 31.8m EUR |
| Net Margin |
6%
|
| Country | FR |
| Market Cap | 6T USD |
| Net Margin |
-21 040%
|
| Country | US |
| Market Cap | 320.1B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 147.4B USD |
| Net Margin |
13%
|
| Country | US |
| Market Cap | 119.4B USD |
| Net Margin |
-5%
|
| Country | US |
| Market Cap | 113.8B USD |
| Net Margin |
0%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Net Margin |
-392%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Net Margin |
18%
|
| Country | US |
| Market Cap | 82.6B USD |
| Net Margin |
34%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Net Margin |
-33%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Net Margin |
-14%
|
Genoway SA
Glance View
genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Genoway SA's most recent financial statements, the company has Net Margin of 5.9%.
You don't have any saved screeners yet
